부산대학교 도서관

Age-related macular degeneration (AMD) is characterized as a chronic, multifactorial disease and is the leading cause of irreversible blindness. Advanced AMD is classified as neovascular (wet) AMD and non-neovascular (dry) AMD. Dry AMD can progress to a more advanced form that manifests as geographic atrophy (GA), which significantly threatens vision, leading to progressive and irreversible loss of visual function. There are currently no approved therapeutics commercially available for GA patients. However, data from various clinical trials have demonstrated favorable results with significant reduction in GA lesion growth. This review furthers the understanding of the pathophysiology of GA, as well as current clinical trial data on investigational therapeutics. Keywords: complement system, gene therapy, neuroprotective agents, personalized treatment, anti-inflammatory agents, intravitreal injection
Introduction Age-related macular degeneration (AMD) is a multifactorial, degenerative disease associated with progressive vision loss, and is more common in developed nations but is prevalent in all countries. (1) AMD [...]